EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 104 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR How to Find Reliable and Affordable Transportation During Cancer January 23, 2024 Health of Gut Microbes May Affect Survival after Stem Cell Transplant March 25, 2020 Smoking Initiation Shifting from Teens to Young Adults November 6, 2020 New on NCI’s Websites for June 2023 June 29, 2023 Load more HOT NEWS Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... Our new strategy to make discoveries, drive progress, and bring hope ESMO Open: First Official Impact Factor of 5.329 Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment
